Total Payments
$4,830
2024 Payments
$706.45
Companies
21
Transactions
75
Medicare Patients
7,224
Medicare Billing
$839,833
Payment Breakdown by Category
Food & Beverage$2,581 (53.4%)
Travel$1,237 (25.6%)
Consulting$785.00 (16.3%)
Education$181.92 (3.8%)
Other$45.00 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,581 | 59 | 53.4% |
| Travel and Lodging | $1,237 | 9 | 25.6% |
| Consulting Fee | $785.00 | 4 | 16.3% |
| Education | $181.92 | 2 | 3.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45.00 | 1 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic, Inc. | $2,288 | 19 | $0 (2023) |
| Abbott Laboratories | $753.02 | 13 | $0 (2019) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $379.25 | 5 | $0 (2024) |
| Medtronic Vascular, Inc. | $359.67 | 4 | $0 (2020) |
| Boston Scientific Corporation | $230.01 | 2 | $0 (2018) |
| PFIZER INC. | $148.83 | 7 | $0 (2024) |
| HEARTFLOW, INC. | $145.18 | 2 | $0 (2024) |
| Amgen Inc. | $117.35 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $79.51 | 4 | $0 (2024) |
| Novo Nordisk Inc | $46.79 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $706.45 | 19 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($159.27) |
| 2023 | $419.05 | 9 | Medtronic, Inc. ($260.00) |
| 2022 | $2,005 | 18 | Medtronic, Inc. ($1,988) |
| 2021 | $40.00 | 1 | Medtronic, Inc. ($40.00) |
| 2020 | $91.13 | 2 | Medtronic Vascular, Inc. ($83.63) |
| 2019 | $94.92 | 2 | Abbott Laboratories ($75.10) |
| 2018 | $272.21 | 6 | Medtronic Vascular, Inc. ($114.61) |
| 2017 | $1,201 | 18 | Abbott Laboratories ($667.26) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $23.03 | General |
| Category: Cardiovascular | ||||||
| 10/02/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $27.37 | General |
| Category: Cardiology | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/10/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $159.27 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 09/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/23/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: Diabetes | ||||||
| 08/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: DIABETES | ||||||
| 07/15/2024 | Philips North America LLC | (5091) Amb Mon & Diag Und (Device) | Food and Beverage | Cash or cash equivalent | $41.49 | General |
| Category: Medical Device | ||||||
| 07/10/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $32.09 | General |
| Category: Cardiology | ||||||
| 07/09/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/25/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: Cardiology | ||||||
| 05/24/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $72.59 | General |
| Category: Coronary | ||||||
| 05/24/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $72.59 | General |
| Category: Coronary | ||||||
| 04/19/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $30.66 | General |
| Category: Not Applicable | ||||||
| 04/16/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/27/2024 | PFIZER INC. | VYNDAQEL (Drug), COMIRNATY | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/11/2024 | Becton, Dickinson and Company | BD Introsyte (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $45.00 | General |
| Category: Vascular/Oncology | ||||||
| 01/11/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/14/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/06/2023 | PFIZER INC. | VYNDAQEL (Drug), COMIRNATY | Food and Beverage | In-kind items and services | $25.58 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/09/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Obesity | ||||||
| 10/18/2023 | PFIZER INC. | VYNDAQEL (Drug), COMIRNATY | Food and Beverage | In-kind items and services | $19.15 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/29/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: Cardiology | ||||||
| 07/20/2023 | Medtronic, Inc. | NITREX (Device) | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| Category: Guidewires | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 2,461 | 2,922 | $452,719 | $131,525 |
| 2022 | 24 | 1,466 | 2,166 | $741,322 | $195,916 |
| 2021 | 18 | 1,681 | 2,635 | $1.1M | $274,903 |
| 2020 | 19 | 1,616 | 2,527 | $943,399 | $237,489 |
Total Patients
7,224
Total Services
10,250
Medicare Billing
$839,833
Procedure Codes
95
All Medicare Procedures & Services
95 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 120 | 256 | $69,120 | $24,513 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 90 | 118 | $40,828 | $11,833 | 29.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 217 | 217 | $40,362 | $11,763 | 29.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 82 | 83 | $43,243 | $11,506 | 26.6% |
| G0422 | Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session | Office | 2023 | 81 | 112 | $36,176 | $11,026 | 30.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 186 | 189 | $35,154 | $9,544 | 27.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 40 | 65 | $31,590 | $9,207 | 29.1% |
| G0423 | Intensive cardiac rehabilitation; with or without continuous ecg monitoring; without exercise, per session | Office | 2023 | 60 | 79 | $25,517 | $7,778 | 30.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $19,756 | $5,289 | 26.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 630 | 742 | $20,840 | $4,828 | 23.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 79 | 79 | $16,274 | $4,632 | 28.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $10,674 | $2,759 | 25.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 25 | 25 | $8,875 | $2,350 | 26.5% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 70 | 108 | $7,560 | $2,082 | 27.5% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 19 | 21 | $8,946 | $1,833 | 20.5% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 93 | 95 | $6,080 | $1,648 | 27.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 24 | $4,512 | $1,470 | 32.6% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 85 | 85 | $4,930 | $1,434 | 29.1% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 108 | 108 | $4,212 | $1,174 | 27.9% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 72 | 122 | $3,782 | $930.60 | 24.6% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 86 | 87 | $3,393 | $895.21 | 26.4% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 43 | 45 | $3,015 | $880.44 | 29.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 70 | 73 | $2,847 | $795.03 | 27.9% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Facility | 2023 | 24 | 24 | $1,656 | $476.43 | 28.8% |
| 93272 | Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | Office | 2023 | 21 | 21 | $1,386 | $350.28 | 25.3% |
About Dr. Gregory Sprung, MD
Dr. Gregory Sprung, MD is a Cardiovascular Disease healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2013. The National Provider Identifier (NPI) number assigned to this provider is 1699018010.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Sprung, MD has received a total of $4,830 in payments from pharmaceutical and medical device companies, with $706.45 received in 2024. These payments were reported across 75 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($2,581).
As a Medicare-enrolled provider, Sprung has provided services to 7,224 Medicare beneficiaries, totaling 10,250 services with total Medicare billing of $839,833. Data is available for 4 years (2020–2023), covering 95 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease, Cardiovascular Disease
- Location Denver, CO
- Active Since 04/03/2013
- Last Updated 08/29/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1699018010
Products in Payments
- VENASEAL (Device) $1,384
- PCI Optimization (Device) $484.00
- EXPORT AP (Device) $440.00
- LifeVest (Device) $379.25
- Resolute (Device) $276.04
- NITREX (Device) $260.00
- WATCHMAN (Device) $230.01
- FFRct (Device) $145.18
- Repatha (Biological) $117.35
- VYNDAQEL (Drug) $109.09
- Reveal LINQ (Device) $83.63
- Absorb (Device) $76.87
- Pacemakers (Device) $75.30
- PressureWire FFR (Device) $75.10
- BD Introsyte (Device) $45.00
- EVEREST (Device) $45.00
- LEQVIO (Drug) $42.70
- (5091) Amb Mon & Diag Und (Device) $41.49
- ELIQUIS (Drug) $40.26
- Launcher (Device) $40.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Denver
Dr. Andrew Freeman, Md, MD
Cardiovascular Disease — Payments: $477,895
Cardiovascular Disease $477,895
Matthew Holland, M.d, M.D
Cardiovascular Disease — Payments: $46,811
Cardiovascular Disease $46,811
Dr. Christopher Barrett, M.d, M.D
Cardiovascular Disease — Payments: $33,700
Cardiovascular Disease $33,700
Alexis Tumolo, M.d, M.D
Cardiovascular Disease — Payments: $32,631
Cardiovascular Disease $32,631
Glenn Hirsch, M.d, M.D
Cardiovascular Disease — Payments: $30,595
Cardiovascular Disease $30,595
Dr. Mori Krantz, Md, MD
Cardiovascular Disease — Payments: $22,589
Cardiovascular Disease $22,589